Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Mach7 Technologies reports loss in fiscal 2026 and focuses on recurring software revenue

Mach7 Technologies called 2026 a transition year: revenue fell 17% to AUD 27.9m, adjusted EBITDA showed a loss of AUD 0.9m and the net loss after tax was AUD 8.9m. Recurring revenue accounted for 84% of sales (AUD 23.4m), contractually secured ARR (CARR) stood at AUD 25.5m. Operating costs fell 16% to AUD 26.7m after restructurings, cash balance is AUD 19.9m with no debt. Management positions 2027 as a proving year focusing on ARR growth, new customers, launch of the Flamingo module and cost discipline; key milestones are RSNA presentations and integrations with Epic and Oracle. » Altro su de.investing.com
Mach7 achieves positive operating cash flow and strengthens cost discipline in year of transition

Mach7 reported positive operating cash flow of A$1.2m in Q3 FY26 and closed the period with A$19.2m in cash and no debt. ARR rose slightly to A$22.8m and CARR to A$25.8m, while operating expenses fell by 15%. The company is pursuing a platform and cloud strategy, launched the modular product Flamingo and is building a partner ecosystem with Dell, AWS and Oracle Cloud. For FY26 management expects revenue to be about 15% below the prior year, but anticipates further efficiency gains and a contribution to ARR from Flamingo in H2 FY26 and FY27. » Altro su de.investing.com
Mach7 Technologies with stable Q3 performance and positive operating cash flow

Mach7 Technologies reports a positive operating cash flow of AUD 1.2m in the third quarter and closed the quarter with a cash position of AUD 19.2m and no debt. Annual recurring revenue rose 2% to AUD 22.8m, CARR stands at AUD 25.8m, and order intake grew 25% to AUD 6m. Operating expenses fell 15%, while the share price remained unchanged at AUD 0.285. The company is focusing on the Flamingo platform and digital pathology; revenue forecasts are USD 23.97m for 2026 and USD 28.28m for 2027. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Mach7 Technologies ha registrato ricavi pari a 8,63 Mln € e un utile netto di -1,93 Mln €

(EUR)	giu 2026	YoY
Ricavi	8,63 Mln	-
Utile lordo	327,21K	-
Utile netto	-1,93 Mln	-
EBITDA	662,81K	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	40,64 Mln €
Numero di azioni	235,01 Mln
Massimo/minimo a 52 settimane	0,42 € - 0,15 €
Dividendi	No
Beta	0,97
Rapporto P/E	-7,37
Rapporto PEG	0,12
Rapporto P/B	1,90
Rapporto P/S	2,36

Profilo aziendale

Mach7 Technologies Limited bietet die gemeinsame Nutzung, Speicherung und Interoperabilität von Bilddaten für Unternehmen im Gesundheitswesen weltweit an. Das Unternehmen ist in zwei Segmenten tätig: Verkauf von Softwarelizenzen und Erbringung von professionellen Dienstleistungen. Das Unternehmen bietet Lösungen für die Unternehmensdiagnose an, darunter eUnity Enterprise Viewer und eUnity Diagnostic Viewer. Darüber hinaus bietet es Lösungen für das Datenmanagement in Unternehmen an, die abteilungs- und unternehmensübergreifende Arbeitsabläufe zur Erfassung, Indizierung, Verwaltung, Speicherung, Verteilung, Anzeige, zum Austausch und zur Analyse von klinischen Bildgebungs- und Multimediainhalten ermöglichen. Darüber hinaus bietet das Unternehmen Enterprise PACS, eine unternehmensfähige Imaging-Plattform, sowie professionelle Dienstleistungen wie Implementierung und Schulung, Datenmigration, Support und Wartungsdienste. Mach7 Technologies Limited wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in South Burlington, Vermont.